Literature DB >> 32142177

Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy.

Rebecca R Valentino1, Shunsuke Koga1, Michael G Heckman2, Danielle E Brushaber3, Nancy N Diehl2, Ronald L Walton1, Dennis W Dickson1, Owen A Ross1,4.   

Abstract

BACKGROUND: Intronic variant rs564309 in tripartite motif containing 11 (TRIM11) is associated with clinical phenotypic differences in progressive supranuclear palsy (PSP), whereby the minor allele (A) is more common in atypical PSP than typical PSP (PSP-Richardson's syndrome). However, rs564309 has not been investigated relative to neuropathological outcomes.
OBJECTIVE: Evaluate the association of rs564309 with the neuropathologically assessed severity of tau pathology, as measured by semi-quantitative scores for neurofibrillary tangles, tufted astrocytes, neuropil threads, and oligodendroglial coiled bodies.
METHODS: 797 neuropathologically confirmed PSP cases were genotyped for TRIM11 rs564309 and assessed for tau pathology across 20 neuroanatomical regions. Tau pathology measures and age at death were examined for association with TRIM11 rs564309-A using multivariable linear regression models.
RESULTS: TRIM11 rs564309-A was associated with increased neurofibrillary tangles pathology (P = 0.050), but was not significantly associated with age at death, neuropil threads, coiled bodies, or tufted astrocytes tau pathology scores.
CONCLUSIONS: TRIM11 rs564309 may influence burden of neurofibrillary tangles tau pathology in PSP; further study is warranted.
© 2020 International Parkinson and Movement Disorder Society. © 2020 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  TRIM11; genetics; neuropathology; progressive supranuclear palsy; tau pathology

Mesh:

Substances:

Year:  2020        PMID: 32142177      PMCID: PMC7528208          DOI: 10.1002/mds.28010

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

1.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

Review 2.  Neuropathology of variants of progressive supranuclear palsy.

Authors:  Dennis W Dickson; Zeshan Ahmed; Avi A Algom; Yoshio Tsuboi; Keith A Josephs
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

Review 3.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration.

Authors:  D W Dickson
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

Review 4.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

5.  Phases of A beta-deposition in the human brain and its relevance for the development of AD.

Authors:  Dietmar R Thal; Udo Rüb; Mario Orantes; Heiko Braak
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

6.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

7.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.

Authors:  Melissa E Murray; Val J Lowe; Neill R Graff-Radford; Amanda M Liesinger; Ashley Cannon; Scott A Przybelski; Bhupendra Rawal; Joseph E Parisi; Ronald C Petersen; Kejal Kantarci; Owen A Ross; Ranjan Duara; David S Knopman; Clifford R Jack; Dennis W Dickson
Journal:  Brain       Date:  2015-03-23       Impact factor: 13.501

8.  Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype.

Authors:  Edwin Jabbari; John Woodside; Manuela M X Tan; Maryam Shoai; Alan Pittman; Raffaele Ferrari; Kin Y Mok; David Zhang; Regina H Reynolds; Rohan de Silva; Max-Joseph Grimm; Gesine Respondek; Ulrich Müller; Safa Al-Sarraj; Stephen M Gentleman; Andrew J Lees; Thomas T Warner; John Hardy; Tamas Revesz; Günter U Höglinger; Janice L Holton; Mina Ryten; Huw R Morris
Journal:  Ann Neurol       Date:  2018-09-15       Impact factor: 10.422

9.  The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy.

Authors:  Edwin Jabbari; John Woodside; Manuela M X Tan; Nicola Pavese; Oliver Bandmann; Boyd C P Ghosh; Luke A Massey; Erica Capps; Tom T Warner; Andrew J Lees; Tamas Revesz; Janice L Holton; Nigel M Williams; Donald G Grosset; Huw R Morris
Journal:  Mov Disord       Date:  2019-07-12       Impact factor: 10.338

10.  APOE ε2 is associated with increased tau pathology in primary tauopathy.

Authors:  Na Zhao; Chia-Chen Liu; Alexandra J Van Ingelgom; Cynthia Linares; Aishe Kurti; Joshua A Knight; Michael G Heckman; Nancy N Diehl; Mitsuru Shinohara; Yuka A Martens; Olivia N Attrebi; Leonard Petrucelli; John D Fryer; Zbigniew K Wszolek; Neill R Graff-Radford; Richard J Caselli; Monica Y Sanchez-Contreras; Rosa Rademakers; Melissa E Murray; Shunsuke Koga; Dennis W Dickson; Owen A Ross; Guojun Bu
Journal:  Nat Commun       Date:  2018-10-22       Impact factor: 17.694

View more
  2 in total

Review 1.  Tauopathies: new perspectives and challenges.

Authors:  Yi Zhang; Kai-Min Wu; Liu Yang; Qiang Dong; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2022-04-07       Impact factor: 14.195

Review 2.  TRIM family proteins: roles in proteostasis and neurodegenerative diseases.

Authors:  Yan Zhu; Lukman O Afolabi; Xiaochun Wan; Joong Sup Shim; Liang Chen
Journal:  Open Biol       Date:  2022-08-10       Impact factor: 7.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.